ULBI Ultralife Corporation

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
July 27, 2023
Date of Report (Date of Earliest Event Reported)
ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware	000-20852	16-1387013
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
2000 Technology Parkway, Newark, New York 14513
(Address of principal executive offices) (Zip Code)
(315) 332-7100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Common Stock, $0.10 par value per share	ULBI	NASDAQ
(Title of each class)	(Trading Symbol)	(Name of each exchange on which registered)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Exhibit Number		Exhibit Description
99.1		Press Release of Ultralife Corporation dated July 27, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Date: July 27, 2023		ULTRALIFE CORPORATION
	By:	/s/ Philip A. Fain
		Philip A. Fain
		Chief Financial Officer and Treasurer

Exhibit 99.1

 

 

 

Ultralife Corporation Reports Second Quarter Results

 

 

NEWARK, N.Y. – July 27, 2023 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2023 with the following highlights:

 

●

Sales of $42.7 million representing a 32.9% year-over-year increase

●

Operating income of $3.7 million compared to $0.8 million for the 2022 second quarter

●

Adjusted EPS of $0.29 compared to $0.03 for the 2022 second quarter

●

Adjusted EBITDA of $6.3 million or 14.7% of sales versus $2.2 million or 6.8% last year

●

Backlog increase to $110.9 million, the highest level in the Company’s history

 

“Driven by surging demand from our government/defense and medical customers, we delivered a 33% year-over-year sales increase to $42.7 million for the second quarter. Leveraged by a sequential improvement in gross margin and disciplined spending, operating profit more than quadrupled from the year-earlier quarter to $3.7 million, the highest level since the third quarter of 2010. With backlog increasing to $110.9 million and durable demand across our diverse end markets, the near-term highest priority remains to recapture gross margin through continued execution of price realization activities, qualification of alternate component suppliers, and lean manufacturing initiatives,” said Mike Manna, President and Chief Executive Officer. “These actions position us to deliver high-quality, sustainable profitable growth for 2023 generating incremental cash flow to pay down our acquisition debt and further invest in our businesses. We continue to strengthen our relationships with our key customers using our global new product development and sales resources to support future growth in target markets.”

 

Second Quarter 2023 Financial Results

 

Revenue was $42.7 million, an increase of $10.6 million, or 32.9%, as compared to revenue of $32.1 million for the second quarter of 2022. Overall, government/defense sales increased 111.5% and commercial sales increased 9.2% over the 2022 period. Battery & Energy Products sales increased 12.3% to $33.9 million, compared to $30.1 million last year, reflecting increases of 26.6% in government/defense sales, 25.2% in medical battery sales, and 17.9% in oil & gas market sales, partially offset by an 18.8% decrease in other commercial sales. Communications Systems sales increased more than four-fold to $8.8 million compared to $2.0 million for the same period last year, primarily attributable to shipments of vehicle-amplifier adaptors to a global defense contractor for the U.S. Army and of integrated systems of amplifiers and radio vehicle mounts to a major international defense contractor under an ongoing allied country government/defense modernization program. Our total backlog exiting the second quarter was $110.9 million representing a 40.1% increase over the comparable period last year with $76.4 million of the total backlog due to ship over the remaining six months of 2023. Total backlog increased $2.8 million or 2.6% compared to the backlog exiting the first quarter.

 

Gross profit was $10.6 million, or 24.8% of revenue, compared to $7.6 million, or 23.8% of revenue, for the same quarter a year ago. Battery & Energy Products’ gross margin was 22.3%, compared to 23.7% last year, primarily due to lingering inefficiencies resulting from the first quarter cyber-attack, disposition of certain non-conforming materials and continued investments in the transition of new products to high volume production, partially offset by improved price realization. Communications Systems gross margin was 34.5% compared to 24.9% last year, primarily due to higher factory volume and favorable product mix.

 

 

Operating expenses were $6.9 million, the same as that reported for the 2022 second quarter. Operating expenses were 16.2% of revenue compared to 21.3% of revenue for the year-earlier period.

 

The combination of higher gross profit and flat operating expenses resulted in a $2.9 million increase in operating income to $3.7 million from $0.8 million last year.

 

Other income, reported below operating income, includes an Employee Retention Credit (“ERC”) for $1.5 million under Section 2301 of the Coronavirus Aid, Relief and Economic Security Act of 2020 and the American Rescue Plan of 2021 which was filed with the Internal Revenue Service during the second quarter of 2023.

 

Net income was $3.3 million or $0.21 per diluted share on a GAAP basis, compared to net income of $0.5 million or $0.03 per diluted share for the second quarter of 2022. Adjusted EPS was $0.29 on a diluted basis for the second quarter of 2023, compared to $0.03 for the 2022 period. Adjusted EPS excludes the provision for deferred taxes of $1.3 million which primarily represents non-cash charges for U.S. taxes which will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.

 

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $6.3 million for the second quarter of 2023, or 14.7% of sales, including the ERC, compared to $2.2 million, or 6.8% of sales, for the year-earlier period.  

 

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EPS to EPS and adjusted EBITDA to net income attributable to Ultralife Corporation.

 

 

About Ultralife Corporation

 

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

 

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

 

 

 

Conference Call Information

 

Ultralife will hold its second quarter earnings conference call today at 8:30 AM ET.

 

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register.vevent.com/register/BI05d612e50dae4c4f91cf91687da98603. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

 

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include the impact of COVID-19 and related supply chain disruptions, potential reductions in revenues from key customers, acceptance of our new products on a global basis and uncertain global economic conditions. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Dollars in Thousands)

(Unaudited)

 

 

ASSETS

 

 

		June 30,				December 31,
		2023				2022
Current Assets:
Cash		$	8,283			$	5,713
Trade Accounts Receivable, Net			28,630				27,779
Inventories, Net			46,063				41,192
Prepaid Expenses and Other Current Assets			4,850				4,304
Total Current Assets			87,826				78,988
Property, Plant and Equipment, Net			21,122				21,716
Goodwill			37,501				37,428
Other Intangible Assets, Net			15,552				15,921
Deferred Income Taxes, Net			11,084				12,069
Other Non-Current Assets			2,307				2,308
Total Assets		$	175,392			$	168,430
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts Payable		$	18,541			$	16,074
Current Portion of Long-Term Debt			2,000				2,000
Accrued Compensation and Related Benefits			2,320				2,890
Accrued Expenses and Other Current Liabilities			6,342				7,949
Total Current Liabilities			29,203				28,913
Long-Term Debt, Net			22,642				19,310
Deferred Income Taxes			1,876				1,917
Other Non-Current Liabilities			1,996				1,887
Total Liabilities			55,717				52,027
Shareholders' Equity:
Common Stock			2,059				2,057
Capital in Excess of Par Value			187,758				187,405
Accumulated Deficit			(44,957	)			(47,951	)
Accumulated Other Comprehensive Loss			(3,846	)			(3,750	)
Treasury Stock			(21,484	)			(21,484	)
Total Ultralife Equity			119,530				116,277
Non-Controlling Interest			145				126
Total Shareholders’ Equity			119,675				116,403
Total Liabilities and Shareholders' Equity		$	175,392			$	168,430

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In Thousands Except Per Share Amounts)

(Unaudited)

 

 

		Three-Month Period Ended								Six-Month Period Ended
		June 30,				June 30,				June 30,				June 30,
		2023				2022				2023				2022
Revenues:
Battery & Energy Products		$	33,861			$	30,140			$	62,331			$	59,290
Communications Systems			8,831				1,986				12,277				3,209
Total Revenues			42,692				32,126				74,608				62,499
Cost of Products Sold:
Battery & Energy Products			26,318				22,989				48,276				45,418
Communications Systems			5,786				1,491				8,308				2,477
Total Cost of Products Sold			32,104				24,480				56,584				47,895
Gross Profit			10,588				7,646				18,024				14,604
Operating Expenses:
Research and Development			1,778				1,672				3,810				3,529
Selling, General and Administrative			5,145				5,181				10,523				10,577
Total Operating Expenses			6,923				6,853				14,333				14,106
Operating Income			3,665				793				3,691				498
Other Income (Expense)			1,058				(115	)			564				(232	)
Income Before Income Taxes			4,723				678				4,255				266
Income Tax Provision (Benefit)			1,375				170				1,242				(81	)
Net Income			3,348				508				3,013				347
Net Income (Loss) Income Attributable to Non-Controlling Interest			8				(4	)			19				3
Net Income Attributable to Ultralife Corporation		$	3,340			$	512			$	2,994			$	344
Net Income Per Share Attributable to Ultralife Common Shareholders – Basic		$	.21			$	.03			$	.19			$	.02
Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted		$	.21			$	.03			$	.19			$	.02
Weighted Average Shares Outstanding – Basic			16,141				16,129				16,138				16,116
Weighted Average Shares Outstanding – Diluted			16,144				16,149				16,141				16,141

 

 

Non-GAAP Financial Measures

 

 

Adjusted EBITDA

 

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to U.S. Generally Accepted Accounting Principles (“GAAP”) financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP.  Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

 

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EBITDA

(Dollars in Thousands)

(Unaudited)

 

		Three-Month Period Ended								Six-Month Period Ended
		June 30, 2023				June 30, 2022				June 30, 2023				June 30, 2022
Net Income Attributable to Ultralife Corporation		$	3,340			$	512			$	2,994			$	344
Adjustments:
Interest Expense, Net			440				177				864				311
Income Tax Provision (Benefit)			1,375				170				1,242				(81	)
Depreciation Expense			760				819				1,522				1,635
Amortization Expense			227				323				436				651
Stock-Based Compensation Expense			154				184				293				373
Cyber-Insurance Policy Deductible			-				-				100				-
Non-Cash Purchase Accounting Adjustment			-				-				-				55
Adjusted EBITDA		$	6,296			$	2,185			$	7,451			$	3,288

 

 

Adjusted Earnings Per Share

 

In evaluating our business, we consider and use adjusted EPS, a non-GAAP financial measure, as a supplemental measure of our business performance.   We define adjusted EPS as net income attributable to Ultralife Corporation excluding the provision (benefit) for deferred income taxes divided by our weighted average shares outstanding on both a basic and diluted basis.  We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that will be predominantly offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future.  We reconcile adjusted EPS to EPS, the most comparable financial measure under GAAP.  Neither current nor potential investors in our securities should rely on adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EPS to EPS and net income attributable to Ultralife Corporation.

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EPS

(In Thousands Except Per Share Amounts)

(Unaudited)

		Three-Month Period Ended
		June 30, 2023												June 30, 2022
		Amount				Per Basic Share				Per Diluted Share				Amount				Per Basic Share				Per Diluted Share
Net Income		$	3,340			$	.21			$	.21			$	512			$	.03			$	.03
Deferred Tax Provision			1,278				.08				.08				27				-				-
Adjusted Net Income		$	4,618			$	.29			$	.29			$	539			$	.03			$	.03
Weighted Average Shares Outstanding							16,141				16,144								16,129				16,149

 

 

		Six-Month Period Ended
		June 30, 2023												June 30, 2022
		Amount				Per Basic Share				Per Diluted Share				Amount				Per Basic Share				Per Diluted Share
Net Income		$	2,994			$	.19			$	.19			$	344			$	.02			$	.02
Deferred Tax Provision (Benefit)			888				.05				.05				(375	)			(.02	)			(.02	)
Adjusted Net Income (Loss)		$	3,882			$	.24			$	.24			$	(31	)		$	.00			$	.00
Weighted Average Shares Outstanding							16,138				16,141								16,116				16,141

 

 

Company Contact:

Ultralife Corporation

Philip A. Fain

(315) 210-6110

pfain@ulbi.com

Investor Relations Contact:

LHA

Jody Burfening

(212) 838-3777

jburfening@lhai.com

 

v3.23.2

Document And Entity Information	Jul. 27, 2023
Document Information [Line Items]
Entity, Registrant Name	ULTRALIFE CORPORATION
Document, Type	8-K
Document, Period End Date	Jul. 27, 2023
Entity, Incorporation, State or Country Code	DE
Entity, File Number	000-20852
Entity, Tax Identification Number	16-1387013
Entity, Address, Address Line One	2000 Technology Parkway
Entity, Address, City or Town	Newark
Entity, Address, State or Province	NY
Entity, Address, Postal Zip Code	14513
City Area Code	315
Local Phone Number	332-7100
Title of 12(b) Security	Common Stock
Trading Symbol	ULBI
Security Exchange Name	NASDAQ
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity, Emerging Growth Company	false
Amendment Flag	false
Entity, Central Index Key	0000875657

---